Biopharma company Jazz Pharmaceuticals (NASDAQ: JAZZ) will be reporting earnings tomorrow after market hours. Here’s what to look for.
Jazz Pharmaceuticals beat analysts’ revenue expectations last quarter, reporting revenues of $1.07 billion, up 19.1% year on year. It was a strong quarter for the company, with a beat of analysts’ EPS estimates.
Is Jazz Pharmaceuticals a buy or sell going into earnings? Read our full analysis here, it’s free for active Edge members.
This quarter, the market is expecting Jazz Pharmaceuticals’s revenue to grow 6.7% year on year, improving from the 2.1% increase it recorded in the same quarter last year.
Analysts covering the company have generally reconfirmed their estimates over the last 30 days, suggesting they anticipate the business will stay the course heading into earnings. Jazz Pharmaceuticals rarely misses Wall Street’s revenue estimates.
Looking at Jazz Pharmaceuticals’s peers in the pharmaceuticals segment, some have already reported their Q2 results, giving us a hint as to what we can expect. Bristol-Myers Squibb delivered year-on-year revenue growth of 5.7%, beating analysts’ expectations by 12.9%, and Corcept reported revenues up 7.3%, falling short of estimates by 1%. Bristol-Myers Squibb traded up 3% following the results while Corcept was also up 27.3%.
Read our full analysis of Bristol-Myers Squibb’s results here and Corcept’s results here.
Investors in the pharmaceuticals segment have had steady hands going into earnings, with share prices flat over the last month. Jazz Pharmaceuticals is up 2.5% during the same time and is heading into earnings with an average analyst price target of $266.90 (compared to the current share price of $250).
ALSO WORTH WATCHING: Nvidia’s Quiet Partner. Nvidia’s chips cost a hundred grand. The connectors that make them work cost even more. One company makes them all.
Every AI server needs specialized infrastructure the chip companies don’t make. High-speed cables. Power connectors. Thermal sensors. This 90-year-old company built a monopoly on it. The AI boom just started. This stock is still flying under the radar. Claim The Stock Ticker Here for FREE.
